PULSION Medical Systems SE reported consolidated earnings results for the third quarter and nine months ended September 30, 2013. For the quarter, the company reported sales of €8.515 million compared to €8.171 million, operating profit of €2.251 million compared to €2.181 million, profit before interest and taxes (EBIT) of €2.198 million compared to €2.205 million, profit before taxes (EBT) of €2.149 million compared to €2.214 million and profit attributable to shareholders of the group parent company of €2.206 million or €0.27 per diluted share compared to €1.510 million or €0.18 per diluted share for the last year. Cash flow from operating activities after changes in net working capital was €391,000 compared to €729,000 and purchase of intangible assets was €417,000 compared to €50,000 for the last year.

For the nine months, the company reported sales of €27.049 million compared to €25.439 million, operating profit of €7.228 million compared to €6.933 million, profit before interest and taxes (EBIT) of €7.006 million compared to €6.998 million, profit before taxes (EBT) of €6.987 million compared to €7.038 million and profit attributable to shareholders of the group parent company of €6.370 million or €0.77 per diluted share compared to €5.127 million or €0.59 per diluted share for the last year. Cash flow from operating activities after changes in net working capital was €2,759,000 compared to €6,442,000 and purchase of intangible assets was €939,000 compared to €63,000 for the last year.

For the full financial year 2013 the company is targeting growth of at least 6%. The company expects EBITDA for the full year to land within a corridor of between €12.5 and €13.0 million. The company continue to predict an EBIT margin for the full year within a target corridor of between 24 % and 28 %. Prediction of earnings per share (EPS) within a range of €0.95 to €1.05, approximately 20 % higher than the previous year's figure of €0.82, remains unchanged.